Prescription Drugs Market to Reach USD 1,562.15 Billion by 2026; Growing Prevalence of Chronic Diseases to Promote Growt

Prescription Drugs Market to Exhibit a CAGR of 8.9% by 2026; Development of Advanced Prescription Drugs to Augment Growth, states Fortune Business Insights™

 

The global prescription drugs market size is predicted to reach USD 1,562.15 billion by 2026, exhibiting a CAGR of 8.9% during the forecast period. The increasing prevalence of chronic diseases, such as cancer, cardiovascular diseases and diabetes will spur sales opportunities for the prescription drugs market revenue during the forecast period. The growing cases of orphan diseases will also have a tremendous impact on the prescription drugs market share. Nonetheless, the ongoing clinical trials by leading players for the development of innovative drugs will enable speedy expansion of the market in the foreseeable future, states Fortune Business Insights in a report, titled “Prescription Drugs Market Size, Share Industry Analysis, By Product Type (Generics, Orphan, and Other Prescription Drugs), By Therapy (Oncology, Anti-diabetics, Vaccines, Sensory Organs, Immunosuppressants, Anticoagulants, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies Drug Stores, and Online Pharmacies), and Regional Forecast, 2019-2026” the market size stood at USD 811.00 billion in 2018.

 

Request Sample PDF @

 https://www.fortunebusinessinsights.com/enquiry/sample/prescription-drugs-market-102709

Major companies in the Global Prescription Drugs Market are increasingly focusing on research and development activities to create new and innovative products to stay ahead of the competition. Staying on top of market trends drivers is crucial for decision-makers to hold this emerging opportunity. The study provides information on market trends and development, drivers, capacities, technologies, and the changing investment structure of the Prescription Drugs Industry.

 

The Report Lists the Key Companies in the Prescription Drugs Market

 

 Novartis AGPfizer, Inc.F. Hoffmann-La Roche LtdSanofi Johnson Johnson Services, Inc Merck Co., Inc. AbbVie, Inc. GlaxoSmithKline plc. AstraZeneca CELGENE CORPORATION (BRISTOL-MYERS SQUIBB COMPANY) Others


Rebecca Rathsfischlers

26 Blog posts

Comments